Executive Summary
The global pharmaceutical and biotechnology sector is entering a period of robust capital spending, driven by a structural shift toward outsourcing and an urgent need for advanced manufacturing capabilities. Active capital expenditures across the globe amount to an estimated $333 billion, distributed across roughly 8,600 active projects. This massive wave of investment reflects a strategic recalibration within the industry.
Thank you, your form has been submitted!
You will receive an email with a copy of the white paper.
If you would like to view other insights, visit our Industrial Insights Podcast Series page.
